MedTrace Logo

Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)

NCT00968929 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2009-09-01

No results posted yet for this study

Summary

Recombinant streptokinase (r-SK) is an effective thrombolytic agent developed with gene engineering. Its characteristics of high output and low production cost make it affordable in treating acute myocardial infarction (AMI) in developing countries. It is unclear whether r-SK can be used in patients with pulmonary embolism (PE). The aim of this study was to investigate the efficacy and safety of 1.5 million IU r-SK by 2 hours infusion and 20,000 IU/kg urokinase (UK) by 2 hours infusion in selected PE patients.

Conditions

Interventions

DRUG

Recombinant Streptokinase

Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours

DRUG

Urokinase

Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours

Sponsors & Collaborators

  • Qingdao University

    collaborator OTHER

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • General Hospital of Shenyang Military Region

    collaborator OTHER

  • Guangdong Institute of Respiratory Disease

    collaborator UNKNOWN

  • The First Affiliated Hospital of Shanxi Medical University

    collaborator OTHER

  • Shenzhen People's Hospital

    collaborator OTHER

  • Ningxia Medical University

    collaborator OTHER

  • Beijing Chao Yang Hospital

    lead OTHER

Principal Investigators

  • Chen WANG, Prof · Beijing Institute of Respiratory Medicine, Beijing-Chao Yang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00968929 on ClinicalTrials.gov